by GOT | Apr 2, 2018 | CutisPharma Press Releases, News
CutisPharma Announces FIRVANQ™ WILMINGTON, Mass. (Apr. 2, 2018) – CutisPharma announced today the commercial launch of FIRVANQ ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by...
by GOT | Mar 26, 2018 | CutisPharma Press Releases, News
NovaQuest Capital Management Acquires CutisPharma, Inc. WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with...
by GOT | Jan 28, 2018 | CutisPharma Press Releases, News
CutisPharma announces FDA approval of FIRVANQ™ CUTISPHARMA ANNOUNCES FDA APPROVAL OF FIRVANQ™ FOR TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA (CDAD) AND STAPHYLOCOCCUS AUREUS COLITIS FDA-approved vancomycin oral liquid therapy expected to improve patient...
Recent Comments